Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial by Claus F. Vogelmeier, Paul W. Jones, Edward M. Kerwin, Isabelle H. Boucot, François Maltais, Lee Tombs, Chris Compton, David A. Lipson, Leif H. Bjermer

Get full text

Early and sustained symptom improvement with umeclidinium/vilanterol monotherapy in COPD: a analysis of the EMAX randomised controlled trial by Edward M Kerwin, Isabelle H Boucot, Claus F Vogelmeier, Francois Maltais, Ian P Naya, Lee Tombs, Paul W Jones, David A Lipson, Tom Keeley, Leif Bjermer

Get full text

Impact of baseline COPD symptom severity on the benefit from dual mono-bronchodilators: an analysis of the EMAX randomised controlled trial by Claus F. Vogelmeier, Edward M. Kerwin, Leif H. Bjermer, Lee Tombs, Paul W. Jones, Isabelle H. Boucot, Ian P. Naya, David A. Lipson, Chris Compton, Neil Barnes, François Maltais

Get full text

Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised tr... by François Maltais, Leif Bjermer, Edward M. Kerwin, Paul W. Jones, Michael L. Watkins, Lee Tombs, Ian P. Naya, Isabelle H. Boucot, David A. Lipson, Chris Compton, Mitra Vahdati-Bolouri, Claus F. Vogelmeier

Get full text